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1. Introduction
Allergic diseases are the most common problem in our community an d globally [1]. Allergic
rhinitis is one of the most common allergic diseases in Iraq and probably in the world and
nowadays it is increasing. It is with a chronic natural history and may appear at any age of life
and subsequently converted into asthma [2] Up to now, there is no curative treatment for
allergic rhinitis and most of the drugs that are used can only induce symptomatic relief and
some of them have serious side effects and can cause withdrawal symptoms which lead the
patients to continue treatment ending in more side effects [1]. There are marked increase in
allergic diseases in developing countries as reported recently [3,4].
Allergic rhinitis with possibility of either under diagnosis in a countries with lower prevalence
or difference in risk factors in these areas of the world [5]. In Iraq, the allergic diseases were
increased with time including AR [6]. To date there were no curative treatment for AR,
however, many pharmacotherapeutic treatment evaluated in different studies and suggested
a variable clinical response [3]. Recently an interest was launched which is the evaluation of
plant products in the treatment of allergic rhinitis [7].
Environmental  control  measures  and  allergen  avoidance,  pharmacological  management,
and immunotherapy are the main three approaches for treatment of allergic rhinitis [8-10].
However,  most of these approaches are palliative and not curative and may be not cost
effective due to the chronicity of the disease [11,12]. Although allergic rhinitis is not a life-
threatening  condition,  various  complications  can  occur  and  result  in  significant  impair‐
ment  in  quality  of  life  [11,12],  eventually  leading  to  increase  medical  cost  and may be
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converted  into  asthma  [1].  Immunotherapy  another  option  of  treatment  is  reserved  for
patients with a less than adequate response to usual treatments and reported to be effective
[13,14]. Although the effectiveness of SIT in the treatment of allergic rhinitis and allergic
asthma has been proven, however its delayed time of action and adverse local and systemic
side effects have limited its use as a treatment modality by majority of the patients [15-19].
Ginger is the rhizome of the plant Zingiber officinal,  belong to Zingiberaceae plant family
and it  used as therapy in ancient medicine,  spice or a tea [20].  Reported studies [21-26]
suggest that ginger extract may exert its benefit as medicine through blocking of seroto‐
nin receptors,  antioxidant  activity,  antiglycating mechanisms.  In  addition,  ginger  extract
may  be  effective  in  treating  nausea,  vomiting  and  heart  burn  [27-31]  and  demonstrate
antibacterial  activity  [32].  However,  the  extract  should  be  not  used  during  pregnancy
because of it is mutagenic [28]. Furthermore, ginger may have analgesic, antipyretic, and
antitumor activity [33-39].
Ginger adverse reactions that include some drugs interaction, increase of bile secretion, and
induction of allergic reaction, may restrict its usage as medicine [40,41]. Since reported studies
suggested the anti-inflammatory, suppressive effects on production of cytokines and reduction
of IgE serum level [42-44], we conduct this study to evaluate the therapeutic effect of ginger
in allergic rhinitis.
Aim of the study:
The aim of this study is to study the clinical and immunological efficacy of Zingiber officinale
(Z.O) on the treatment of allergic rhinitis.
2. Materials and methods
2.1. Patients
A total of 79 patients allergic rhinitis were included in the study. Those patients were recruited
from patients attending Aljumhory Teaching Hospital in Mosul and were selected on the basis
that was with high total IgE serum levels. The study done during the period from November
2010 to October 2012. The patients were with age of > 10 years old. The patients divided into
active and control group. The active group includes 42 patient and 37 patients were in control
group. Each patients in active group received Zingiber officinale (Z.O) capsules, twice daily
after meal. While each patient in control group received the same dose of sucrose powder
capsules for 2 months, through which clinical follow up occurred completely in each monthly
visit with recording the notes.
2.2. Diagnosis of asthma and allergic rhinitis
Allergic rhinitis diagnosis was performed according to previously reported guidelines [45].
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2.3. Skin prick test
The skin prick tests were performed for all patients and control and evaluated in accordance
with European Academy of Allergy and Clinical [1]. Immunology subcommittee on allergy
standardization and skin tests using standards allergen panel (Stallergen, France). The panel
for skin test include: dust mite (Dermatophagoides farina, Dermatophagoides peteronyssi‐
nus), Aleternaria, Cladosprium, Penicillum mixture, Aspergillus mixture, Grasses mixture,
Feather mixture, Dog hair, Horse hair, Cat fur, Fagacae, Oleaceae, Betulaceae, Plantain,
Bermuda grass, Chenopodium and Mugworth. All tests were performed in the outpatient
Asthma and Allergy Centre, Mosul by a physician using a commercial allergen extracts
(Stallergen, France) and a lancet skin prick test device. A wheal diameter of 3 mm or more in
excess of the negative control was considered as positive test result.
2.4. Determination of total serum IgE
ELISA was performed to estimate the total serum IgE level as a serological marker for treatment
response monitoring [1]. Total serum IgE was determined by enzyme linked immunosorbant
assay kit (Biomaghreb). Results were interpreted as allergy not probable if serum IgE was lower
than 20 IU/ml, allergy is possible if IgE value is between 20 and 120 IU/ml and allergy is very
probable if IgE is more than 120 IU/ml.
2.5. Treatment schedule and assessment
Z. officinale was given as capsules, one capsule twice daily after each meal. Each capsule
contained about 0.5 gm (500 mg) of Z.O powder.
The control group received the same capsules but they were contained sucrose sugar powder,
the treatment was given for 2 months. The results were recorded on the patient's questionnaire
in each visit. The same routine physical examination & laboratory investigations as mentioned
earlier were done in each visit & recorded with clinical evaluation which was done according
to the following criteria and as reported previously[6]:
1. Clinical assessment (symptoms score); during each visit, the patients was examined
clinically for vital signs & questioned about the improvement in his day & night symptoms
(rhinorrhoea, nasal obstruction, paroxysm of sneezing, night snoring, chest tightness,
wheezes, cough, shortness of breath, work & school attendance, skin wheals, itchy skin,
swelling & the lip or eye lid, shortness on exertion.....etc).
2. Tolerability to the exacerbating factors: Many precipitating factors such as aeroallergens
exposure, cold exposure, infection (sinusitis), drugs, exertion....etc. may precipitate the
condition, so the response to the exacerbating factors were assessed in each visit.
2.6. Side effects
Side effects that were shown by the patients were recorded in all patients & for all allergies
type.
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2.7. Statistical analysis
SPSS version 19 analytic system: Paired Samples test; Independent Samples test & Descriptive
Statistics were used to compare between active & placebo groups. Chi square also was used
in this statistics of the research.
3. Results
3.1. Baseline estimation
A total of 79 patients were included, 51.9 % (41patients) male and 48.1% (38 patients) female.
Those patients were classified according to their disease pattern into seasonal 39.2 % (31
patients) and perennial 60.7 % (48 patients), of the total 49.3 % (39 patients) had positive family
history of atopic diseases while 50.6 % (40 patients) were with negative family history of atopic
disease. They were subdivided into active (42 patients) and control group (37 patients) as show
in Table 1.
Total number 79
Gender Male 41Female 38
Type Seasonal 31Perennial 48
Family history Positive 39Negative 40
Smoking Positive 27Negative 52
Subgroups Active 42Control 37
Table 1. Allergic rhinitis patients baseline information.
3.2. Frequency distribution of the patients according to the age
Table 2 shows the frequency distribution of patients according to their ages. It shows that the
peak incidence age occurred within the age of 10-19 years which account for 30.3% (24 patients).
Age/year Number of patients
10-19 years 24 (30.3%)
20-29 years 19 (24%)
30-39 years 16 (20.2%)
40- above 20 (25.3%)
Table 2. Frequency distribution of the patients according to the age
Allergic Diseases - New Insights156
3.3. Frequency distribution of the patients according to the duration of the disease
Table 3 shows the frequency distribution of the patients according to their duration of the
disease. It shows that the peak incidence duration of the disease range between 1-5 years and
this account for 64.5% (51patients).
Duration/ years Number of patients
1-5 years 51 (64.5%)
6-10 years 14 (17.7%)
11-15 years 8 (10.1%)
16-20 years 1 (1.2%)
21- above years 5 (6.3%)
Table 3. Frequency distribution of the patients according to the duration of the disease
3.4. Relationship between family history of atopic disease and total IgE level in allergic
rhinitis patients
The relationship between family history of atopic disease and total IgE level in allergic rhinitis
patients is shown in Table 4. There was a significant relationship (p= 0.001) between family
history of atopy and total IgE serum level.
Family history of
atopy Patients number mean Standard deviation P value
Negative history 40 206.8 54.9
0.001Positive history 39 335.2 223.2
Independent Samples test
Table 4. Relationship between family history of atopic disease and total IgE level in allergic rhinitis patients
3.5. Relationship between smoking and total IgE level in allergic rhinitis patients
There was a non-significant relationship (p=0.124) between smoking and total IgE serum level
in allergic rhinitis as shown in (Table 5).
Smoking Patients number Mean Standard deviation P value
Negative history 52 248.5 146.8
0.124
Positive history 27 311.9 211.6
Independent Samples test
Table 5. Relationship between smoking and total IgE level in allergic rhinitis patients
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3.6. Subgroups of allergic rhinitis patients
Table 6 shows the subgroups of allergic rhinitis patients : active group of allergic rhinitis included
42 patients (22 male, 20 female), (19 seasonal, 23 perennial), (21 positive family history of atopy
while 21 with negative family history),(28 smoking cigarette while 14 not smoking cigarette).
On the other hand, control group included 37(19 male,18 female), (12 seasonal,25 perennial),
(18 had positive family history of atopy while 19 had not),(25 smoke cigarette, 12 not).
Group Active Control
Number 42 37
Sex Male 22 19Female 20 18
Type Seasonal 19 12Perennial 23 25
Family history Positive 21 18negative 21 19
Smoke Positive 28 25negative 14 12
Table 6. Subgroups of allergic rhinitis patients
3.7. Immunological effect (on total IgE level) after 2 months treatment
The effect of treatment on total IgE level is shown in Table 7 : It shows that the effect of Z.
officinale is highly significant after the first month of treatment (p = 0.027) which also stayed
significant after the second month treatment (p =0.002). While in case of placebo capsules, there
is no significant decrease in the level of total IgE after first month (p= 0.112) nor after second
month (p= 0.64).
Group Month Number ofpatients Mean
Standard
deviation P value
Active
0 42 258.4 170.5 -------
1 42 229.3 133.7 0.027
2 42 175.7 85.5 0.002
Control
0 37 383.6 177.2 ------
1 37 256.1 157.8 0.112
2 37 239.2 108.5 0.64
Table 7. Immunological Effect of treatment on Total IgE level in AR patients
3.8. Clinical effect after 2 months treatment
Clinical improvement after 2 months of treatment for both groups is seen in Table 8, from total,
78.5 %(33 patients) were improved in the active group after first month of treatment while 21.4
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%(9 patients) were improved from placebo treating group. There was a significant difference
(p=0.010) between active and placebo treated groups. At the end of 2nd month, the result stayed
significant (p=0.011) with 92.8 %(39 patients) were improved from active group corresponding
to 35.1 %(13 patients) were improved from placebo treating group.
Months of
Treatment Subgroups
Improved patients
Number
Not improved
Patients
Number
P value
Month 1
Active 33 (78.5%) 9 (21.4%)
0.010
Control 10 (27 %) 27 (72.9 %)
Month 2
Active 39 (92.8%) 3 (7.1%)
0.011
Control 13 (35.1 %) 24 (64.8 %)
Table 8. Clinical improvement in general condition in A.R patients after treatment
3.9. Effect on specific clinical features
The comparison between the improvement in specific nasal allergic symptoms in both
subgroups(experimental and placebo) after 2 months of treatment is shown in Table 9. It shows
that sinusitis had improved in 83.3% (35 patient) of experimental group while only 21.6% (8
patients) in control group demonstrate improvement and this difference was signifi‐
cant(p=0.002). Nasal itching had improved in 78.5% (33 patients) in experimental patients
while it improved in 32.4 % (12 patients) in control group (p=0.027). While rhinorrhoea had
improved in 69.0% (29 patients) in active group corresponding to 37.8 % (14 patients) in control
group which is insignificant (p=0.126). Sneezing had decreased in 61.9% (26 patients) in
experimental group while in control group it had improved in 24.3%(9 patients) with signifi‐
cant difference (p=0.033).
Clinical features Active group
improved patients
Control group
patients improved
P value
Sinusitis 35 (83.3%) 8 (21.6%) 0.002
Nasal itching 33 (78.5%) 12 (32.4%) 0.027
Rhinorrhoea 29 (69.0%) 14 (37.8%) 0.126
Sneezing 26 (61.9%) 9 (24.3%) 0.033
Post nasal drainage 17 (40.4%) 5 (13.5%) 0.042
Conjunctivitis 11 (26.1%) 6 (16.2%) 0.385
Others 8 (19.0%) 4 (10.8%) 0.381
Chi square test
Table 9. Effect on specific clinical features after 2 months treatment
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Post nasal drainage had decreased significantly (p=0.042) in 40.4% (17 patients) of active group
while it had decreased in 13.5 % (5 patients) of control group. Conjunctivitis had decreased in
26.1% (11 patients) in experimental group but it had decreased in 16.2% (6 patients) in control
group, but not with significant difference (p=0.381) result.
3.10. Medication score
Medication score of conventional therapy had been decreased in 71.4 % (30 patients) in active
group and in 27.4 % (10 patients) in control in 1st month of treatment and the difference was
significant (p=0.021). The significance degree became larger in the second month (p=0.004),
which statistically measured the results of decreased conventional therapy use in active group
which account for 88 % (37 patients) corresponding to 27 %(10 patients) in the placebo treating
group.
Months of
treatment Subgroups
Patients with decreased
medication
Patients not with
decreased medications P value
Month 1
Active 30(71.4%)
12
(28.5%)
0.021
Control 10(27%)
27
(72.9%)
Month 2
Active 37(88%)
5
(11.9%)
0.004
Control 10(27%)
27
(72.9%)
Chi square test
Table 10. Medication score
4. Discussion
Pharmacotherapy is still the corner stone in the management of allergic disease followed by
immunotherapy. All therapeutic strategies have many side effects. Some of them may prove
dangerous or even lethal, in addition, mostly there is no curative therapy [3,4]. One of the good
substitutions is the use of herbal medicine and one of the ancient herb that was used medically
for many diseases was Zingiber officinale [21,22]. This herb has been used for many diseases
since no signs of serious adverse effects were known in antiquity.
Male were affected slightly more with AR than female. This result accords with other studies
that showed no sex difference or slight male predominance [46]. About 54% of patients were
less than 30 years old which means that the onset mainly started at the days of childhood
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adolescence. This goes in line with other studies [47] because allergy is a less common cause
of rhinitis in elderly as compared with form of rhinitis like atrophic rhinitis [48].
Concerning duration of the disease, 64.5% of patients had duration less than 5 years. That
means the allergic state in Iraq increased progressively in the last years especially after the last
war in 2003 due to increased air pollutions. Our study demonstrated a significant association
between family history and IgE serum level in allergic rhinitis patients. This finding is in
accordance with well documented fact in allergic diseases [49-51].
The present study not shows a significant relationship between smoking and IgE serum level
and this result is not agreed with that reported for Canada [52]. Z.O treatment showed a
significant effect on total IgE level. This is not strange for Z.O because it has potent immuno‐
logical effect in different studies [42-44]. Ginger extract seems to be with a wide range of
therapeutic effects that include multiorgan [53] such as the immune response, metabolism, and
gastrointestinal.
In the present study the patients showed excellent improvement in clinical symptoms and
clinical response after 2 months treatment duration especially in patients as compared with
control group. This may be due to the anti-mucous effect mainly, in addition to anti allergic
effect that present in its contents. Ginger demonstrate effective therapeutic effects in the
treatment of asthma and other respiratory diseases through its ability to loosen and expel
phlegm from the sinuses and lungs [42].
In Japanese cedar pollinosis patients, and in the most sever cedar pollen scattering period,
allergy symptoms (blowing the nose, itching eyes....etc) were significantly relieved in experi‐
mental group taking tea containing ginger extract for 13 weeks as compared with placebo
group. Stuffy nose, sore throat medication score were significantly relieved. [54].
Medication score showed good decrease in conventional treatment of allergic rhinitis after 2
months uses of Z.O therapy as compared with control group. These results were a reflection
and explanation of the improvement in clinical symptoms and augment the idea that says
herbal treatment is benefit in medical fields.
In conclusion, Zingiber officinale is effective treatment for allergic rhinitis and significantly
reduced serum total IgE after 4 weeks of treatment course.
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